StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for NMTC yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $4.20 | $4.53 | +7.86% | 0.0M |
| 05-19 | $4.49 | $4.11 | -8.46% | 0.0M |
| 05-20 | $4.20 | $4.09 | -2.62% | 0.0M |
| 05-21 | $3.99 | $3.90 | -2.26% | 0.0M |
| 05-22 | $3.95 | $3.69 | -6.50% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Annual 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $5.28M | $2.89M | $9.10M | $6.36M |
Operating Income | $-3.81M | $-1.71M | $-4.23M | $-2.86M |
Net Income | $-3.52M | $-1.44M | $-3.61M | $-1.99M |
EPS (Diluted) | $-0.44 | $-0.03 | $-0.09 | $-0.05 |
Total Assets | $7.86M | $8.58M | $10.79M | $10.82M |
Total Liabilities | $2.49M | $2.18M | $3.71M | $2.64M |
Cash & Equivalents | $2.80M | $3.56M | $6.57M | $8.04M |
Free Cash Flow OCF − CapEx | $-4.52M | $-3.16M | $-2.92M | $-1.38M |
Shares Outstanding | 8.62M | 50.41M | 8.33M | 49.82M |